Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation,Allergy

当前位置： X-MOL 学术 › Allergy › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation
Allergy ( IF 12.6 ) Pub Date : 2020-01-03 , DOI: 10.1111/all.14151
Audrey Le Floc'h ₁ , Jeanne Allinne ₁ , Kirsten Nagashima ₁ , George Scott ₁ , Dylan Birchard ₁ , Seblewongel Asrat ₁ , Yu Bai ₁ , Wei Keat Lim ₁ , Joel Martin ₁ , Tammy Huang ₁ , Terra B Potocky ₁ , Jee H Kim ₁ , Ashique Rafique ₁ , Nicholas J Papadopoulos ₁ , Neil Stahl ₁ , George D Yancopoulos ₁ , Andrew J Murphy ₁ , Matthew A Sleeman ₁ , Jamie M Orengo ₁

Affiliation

Dupilumab, a fully human monoclonal antibody that binds IL‐4Rα and inhibits signaling of both IL‐4 and IL‐13, has shown efficacy across multiple diseases with underlying type 2 signatures and is approved for treatment of asthma, atopic dermatitis, and chronic sinusitis with nasal polyposis. We sought to provide a comprehensive analysis of the redundant and distinct roles of IL‐4 and IL‐13 in type 2 inflammation and report dupilumab mechanisms of action.

中文翻译：

需要用一种 IL-4Rα 抗体 dupilumab 双重阻断 IL-4 和 IL-13 以广泛抑制 2 型炎症

Dupilumab 是一种完全人源性单克隆抗体，可结合 IL-4Rα 并抑制 IL-4 和 IL-13 的信号传导，已在具有潜在 2 型特征的多种疾病中显示出疗效，并被批准用于治疗哮喘、特应性皮炎和慢性鼻窦炎伴有鼻息肉。我们试图对 IL-4 和 IL-13 在 2 型炎症中的冗余和独特作用进行全面分析，并报告 dupilumab 的作用机制。

更新日期：2020-01-03

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南